Circulation. 2001;104:2280-2288
Published online before print October 15, 2001, doi: 10.1161/hc4401.100078
Published online before print October 15, 2001, doi: 10.1161/hc4401.100078
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2001;104:2280.)
© 2001 American Heart Association, Inc.
Clinical Investigations and Reports |
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
From the Division of Cardiology, New England Medical Center, Boston, Mass (M.A.K.); the Nephrology Division, University of Maryland Hospital, Baltimore (M.R.W.); and Merck Research Laboratory, Merck, Whitehouse Station, NJ (A.R., D.S., R.S.S., E.B., B.J.G.).
Correspondence to Dr Marvin A. Konstam, New England Medical Center, Division of Cardiology, 750 Washington Street, Boston, MA 02111-1533. E-mail MKonstam{at}Lifespan.org
Background— In comparing aspirin, nonselective nonsteroidal antiinflammatory agents (NSAIDs), and cyclooxygenase (COX)-2 inhibitors, variation in platelet inhibitory effects exists that may be associated with differential risks of cardiovascular (CV) thrombotic events. Among the randomized, controlled trials with the COX-2 inhibitor rofecoxib, one study demonstrated a significant difference between rofecoxib and its NSAID comparator (naproxen) in the risk of CV thrombotic events. A combined analysis of individual patient data was undertaken to determine whether there was an excess of CV thrombotic events in patients treated with rofecoxib compared with those treated with placebo or nonselective NSAIDs.
Methods and Results— CV thrombotic events were assessed across 23 phase IIb to V rofecoxib studies. Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone). The major outcome measure was the combined end point used by the Antiplatelet Trialists’ Collaboration, which includes CV, hemorrhagic, and unknown deaths; nonfatal myocardial infarctions; and nonfatal strokes. More than 28 000 patients, representing >14 000 patient-years at risk, were analyzed. The relative risk for an end point was 0.84 (95% CI: 0.51, 1.38) when comparing rofecoxib with placebo; 0.79 (95% CI: 0.40, 1.55) when comparing rofecoxib with non-naproxen NSAIDs; and 1.69 (95% CI: 1.07, 2.69) when comparing rofecoxib with naproxen.
Conclusions— This analysis provides no evidence for an excess of CV events for rofecoxib relative to either placebo or the non-naproxen NSAIDs that were studied. Differences observed between rofecoxib and naproxen are likely the result of the antiplatelet effects of the latter agent.
Key Words: rofecoxib • anti-inflammatory agents, nonsteroidal • cardiovascular diseases • thrombosis
This article has been cited by other articles:
 |
|
 |
|
  B. M. Psaty and R. A. Kronmal Reporting Mortality Findings in Trials of Rofecoxib for Alzheimer Disease or Cognitive Impairment: A Case Study Based on Documents From Rofecoxib Litigation JAMA, April 16, 2008; 299(15): 1813 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Hennekens and S. Borzak Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 41 - 50. [Abstract] [PDF]
|
|
|
|
 |
|
 W. A. Ray Learning from Aprotinin -- Mandatory Trials of Comparative Efficacy and Safety Needed N. Engl. J. Med., February 21, 2008; 358(8): 840 - 842. [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Joshi, R. Gertler, and R. Fricker Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs Anesth. Analg., December 1, 2007; 105(6): 1793 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P A Scott, G H Kingsley, C M Smith, E H Choy, and D L Scott Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials Ann Rheum Dis, October 1, 2007; 66(10): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. White Cardiovascular Effects of the Cyclooxygenase Inhibitors Hypertension, March 1, 2007; 49(3): 408 - 418. [Full Text] [PDF]
|
|
|
|
 |
|
 A. W Jorgensen, J. Hilden, and P. C Gotzsche Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review BMJ, October 14, 2006; 333(7572): 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hur, A. T Chan, A. C Tramontano, and G S. Gazelle Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs Ann. Pharmacother., June 1, 2006; 40(6): 1052 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Harris and M. D. Breyer Update on Cyclooxygenase-2 Inhibitors Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 236 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Etminan, S. Gill, M. FitzGerald, and A. Samii Challenges and Opportunities for Pharmacoepidemiology in Drug-Therapy Decision Making J. Clin. Pharmacol., January 1, 2006; 46(1): 6 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pratico and J.-M. Dogne Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine Circulation, August 16, 2005; 112(7): 1073 - 1079. [Full Text] [PDF]
|
|
|
|
|
|
B. F. McAdam, D. Byrne, J. D. Morrow, and J. A. Oates Contribution of Cyclooxygenase-2 to Elevated Biosynthesis of Thromboxane A2 and Prostacyclin in Cigarette Smokers Circulation, August 16, 2005; 112(7): 1024 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Braunstein and A. Polis Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial Ann Intern Med, July 19, 2005; 143(2): 158 - 159. [Full Text] [PDF]
|
|
|
|
|
|
M. Hudson, H. Richard, and L. Pilote Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study BMJ, June 11, 2005; 330(7504): 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Johnsen, H. Larsson, R. E. Tarone, J. K. McLaughlin, B. Norgard, S. Friis, and H. T. Sorensen Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study Arch Intern Med, May 9, 2005; 165(9): 978 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Zhang, M Doherty, N Arden, B Bannwarth, J Bijlsma, K-P Gunther, H J Hauselmann, G Herrero-Beaumont, K Jordan, P Kaklamanis, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis, May 1, 2005; 64(5): 669 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Levesque, J. M. Brophy, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Ann Intern Med, April 5, 2005; 142(7): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Solomon, J. J.V. McMurray, M. A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W. F. Anderson, A. Zauber, E. Hawk, M. Bertagnolli, et al. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention N. Engl. J. Med., March 17, 2005; 352(11): 1071 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Nussmeier, A. A. Whelton, M. T. Brown, R. M. Langford, A. Hoeft, J. L. Parlow, S. W. Boyce, and K. M. Verburg Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery N. Engl. J. Med., March 17, 2005; 352(11): 1081 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Bresalier, R. S. Sandler, H. Quan, J. A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, et al. Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial N. Engl. J. Med., March 17, 2005; 352(11): 1092 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-J. Aw, S. J. Haas, D. Liew, and H. Krum Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure Arch Intern Med, March 14, 2005; 165(5): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kimmel, J. A. Berlin, M. Reilly, J. Jaskowiak, L. Kishel, J. Chittams, and B. L. Strom Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction Ann Intern Med, February 1, 2005; 142(3): 157 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Finckh and M. D. Aronson Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now Ann Intern Med, February 1, 2005; 142(3): 212 - 214. [Full Text] [PDF]
|
|
|
|
|
|
F. T. Shaya, S. W. Blume, C. M. Blanchette, M. R. Weir, and C. D. Mullins Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population Arch Intern Med, January 24, 2005; 165(2): 181 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Kim, A. S. Reicin, L. Villalba, J. Witter, M. M. Wolfe, and E. J. Topol Rofecoxib, Merck, and the FDA N. Engl. J. Med., December 30, 2004; 351(27): 2875 - 2878. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Buerkle, S. Lehrer, H.-Y. Sohn, P. Conzen, U. Pohl, and F. Krotz Selective Inhibition of Cyclooxygenase-2 Enhances Platelet Adhesion in Hamster Arterioles In Vivo Circulation, October 5, 2004; 110(14): 2053 - 2059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Patrono, B. Coller, G. A. FitzGerald, J. Hirsh, and G. Roth Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 234S - 264S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bogaty, J. M. Brophy, M. Noel, L. Boyer, S. Simard, F. Bertrand, and G. R. Dagenais Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein: A Randomized Placebo-Controlled Study Circulation, August 24, 2004; 110(8): 934 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Lisse, M. Perlman, A. B. Polis, and G. P. Geba Tolerability of Rofecoxib versus Naproxen Ann Intern Med, June 15, 2004; 140(12): 1060 - 1060. [Full Text] [PDF]
|
|
|
|
|
|
M. L. Jenkinson Tolerability of Rofecoxib versus Naproxen Ann Intern Med, June 15, 2004; 140(12): 1059 - 1060. [Full Text] [PDF]
|
|
|
|
|
|
D. H. Solomon, S. Schneeweiss, R. J. Glynn, Y. Kiyota, R. Levin, H. Mogun, and J. Avorn Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults Circulation, May 4, 2004; 109(17): 2068 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. WARNER and J. A. MITCHELL Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J, May 1, 2004; 18(7): 790 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. N. Patel and K. C. Goldberg Use of Aspirin and Ibuprofen Compared With Aspirin Alone and the Risk of Myocardial Infarction Arch Intern Med, April 26, 2004; 164(8): 852 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M J James and L G Cleland Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib J. Med. Ethics, April 1, 2004; 30(2): 182 - 184. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. A. Howard and P. Delafontaine Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk J. Am. Coll. Cardiol., February 18, 2004; 43(4): 519 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Title, K. Giddens, M. M. McInerney, M. J. McQueen, and B. A. Nassar Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1747 - 1753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Verma and P. E. Szmitko Coxibs and the endothelium J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1754 - 1756. [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Hankey and J. W. Eikelboom Cyclooxygenase-2 Inhibitors: Are They Really Atherothrombotic, and If Not, Why Not? Stroke, November 1, 2003; 34(11): 2736 - 2740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Layton, E. Heeley, K. Hughes, and S. A. W. Shakir Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data Rheumatology, November 1, 2003; 42(11): 1342 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Layton, K. Hughes, S. Harris, and S. A.W. Shakir Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data Rheumatology, November 1, 2003; 42(11): 1354 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Lisse, M. Perlman, G. Johansson, J. R. Shoemaker, J. Schechtman, C. S. Skalky, M. E. Dixon, A. B. Polis, A. J. Mollen, G. P. Geba, et al. Gastrointestinal Tolerability and Effectiveness of Rofecoxib versus Naproxen in the Treatment of Osteoarthritis: A Randomized, Controlled Trial Ann Intern Med, October 7, 2003; 139(7): 539 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. S. Koo Acute Pain Management Journal of Pharmacy Practice, August 1, 2003; 16(4): 231 - 248. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Ng, G. Smith, and A. C. Davidson Analgesic effects of parecoxib following total abdominal hysterectomy{dagger}{ddagger} Br. J. Anaesth., June 1, 2003; 90(6): 746 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Ott, N. A. Nussmeier, P. C. Duke, R. O. Feneck, R. P. Alston, M. C. Snabes, R. C. Hubbard, P. H. Hsu, L. J. Saidman, and D. T. Mangano Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery J. Thorac. Cardiovasc. Surg., June 1, 2003; 125(6): 1481 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tuleja, F. Mejza, A. Cmiel, and A. Szczeklik Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1111 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Rott, J. Zhu, M. S. Burnett, Y. i F. u Zhou, A. Zalles-Ganley, J. Ogunmakinwa, and S. E. Epstein Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice J. Am. Coll. Cardiol., May 21, 2003; 41(10): 1812 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chenevard, D. Hurlimann, M. Bechir, F. Enseleit, L. Spieker, M. Hermann, W. Riesen, S. Gay, R. E. Gay, M. Neidhart, et al. Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease Circulation, January 28, 2003; 107(3): 405 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Juni, P. Dieppe, M. Egger, D. Solomon, J. Avorn, R. J. Glynn, E. Rahme, L. Pilote, J. LeLorier, D. J. Watson, et al. Risk of Myocardial Infarction Associated With Selective COX-2 Inhibitors: Questions Remain Arch Intern Med, December 9, 2002; 162(22): 2639 - 2642. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wright The double-edged sword of COX-2 selective NSAIDs Can. Med. Assoc. J., November 12, 2002; 167(10): 1131 - 1137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Vogt, G. Navis, and D. de Zeeuw Renoprotection: A Matter of Blood Pressure Reduction or Agent-Characteristics? J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S202 - 207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jaeschke, P. Gajewski, and J. Brozek Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib Circulation, July 30, 2002; 106 (5): e18 - e18. [Full Text] [PDF]
|
|
|
|
|
|
B. Pitt, C. Pepine, and J. T. Willerson Cyclooxygenase-2 Inhibition and Cardiovascular Events Circulation, July 9, 2002; 106(2): 167 - 169. [Full Text] [PDF]
|
|
|
|
|
|
R. Altman, H. L. Luciardi, J. Muntaner, F. Del Rio, S. G. Berman, R. Lopez, and C. Gonzalez Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation: The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study Circulation, July 9, 2002; 106(2): 191 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Wooltorton What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex) Can. Med. Assoc. J., June 1, 2002; 166(13): 1692 - 1693. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Dalen Selective COX-2 Inhibitors, NSAIDs, Aspirin, and Myocardial Infarction Arch Intern Med, May 27, 2002; 162(10): 1091 - 1092. [Full Text] [PDF]
|
|
|
|
|
|
M. K. Halushka and P. V. Halushka Why Are Some Individuals Resistant to the Cardioprotective Effects of Aspirin?: Could It Be Thromboxane A2? Circulation, April 9, 2002; 105(14): 1620 - 1622. [Full Text] [PDF]
|
|
|
|
|
|
L. J. Crofford Rational Use of Analgesic and Antiinflammatory Drugs N. Engl. J. Med., December 20, 2001; 345(25): 1844 - 1846. [Full Text] [PDF]
|
|
|
|
|
|
T. G. Burnakis, M. Fleming, M. A. Konstam, L. A. Demopoulos, K. D. Grant, E. J. Haldey, M. Pappagallo, M. Minic, P. L. McGeer, E. G. McGeer, et al. Cardiovascular Events and COX-2 Inhibitors JAMA, December 12, 2001; 286(22): 2808 - 2813. [Full Text] [PDF]
|
|
|
|
|
|
N. C. Lai, D. M. Roth, M. H. Gao, S. Fine, B. P. Head, J. Zhu, M. D. McKirnan, C. Kwong, N. Dalton, K. Urasawa, et al. Intracoronary Delivery of Adenovirus Encoding Adenylyl Cyclase VI Increases Left Ventricular Function and cAMP-Generating Capacity Circulation, October 25, 2000; (2000) 10. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Levesque, J. M. Brophy, and B. Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Ann Intern Med, April 5, 2005; 142(7): 481 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Burleigh, V. R. Babaev, J. A. Oates, R. C. Harris, S. Gautam, D. Riendeau, L. J. Marnett, J. D. Morrow, S. Fazio, and M. F. Linton Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor-Deficient Mice Circulation, April 16, 2002; 105(15): 1816 - 1823. [Abstract] [Full Text] [PDF]
|
|